Background/Objectives: Peptide-based treatments represent an expanding area and require innovative approaches to enhance bioavailability. Combination with cell-penetrating peptides (CPPs) is an attractive strategy to improve non-invasive delivery across nasal epithelial barriers for systemic and direct nose-to-brain transport. We previously developed a modified CPP system termed Glycosaminoglycan-binding Enhanced Transduction (GET) that improves insulin delivery across gastrointestinal epithelium. It contains a membrane docking sequence to promote cellular interactions (P21), a cationic polyarginine domain to stimulate uptake (8R) and an endosomal escaping sequence to maximize availability for onward distribution (LK15). It is synthesized as a single 44-residue peptide (P21-LK15-8R; PLR). Methods: The current research used in vitro assays for a novel exploration of PLR’s ability to improve the transport of two contrasting peptides, insulin (51 residues, net negative charge) and oxytocin (9 residues, weak positive charge) across an RPMI 2650 human nasal epithelial cell barrier cultured at the air–liquid interface. Results: PLR enhanced insulin transcytosis over a 6 h period by 7.8-fold when used at a 2:1 molar ratio of insulin/PLR (p < 0.0001 versus insulin alone). Enhanced oxytocin transcytosis (5-fold) occurred with a 1:10 ratio of oytocin/PLR (p < 0.01). Importantly, these were independent of any impact on transepithelial electrical resistance (TEER) or cell viability (p > 0.05). Conclusions: We advocate the continued evaluation of insulin–PLR and oxytocin–PLR formulations, including longer-term assessments of ciliotoxicity and cytotoxicity in vitro followed by in vivo assessments of systemic and nose-to-brain delivery.
Diabetes mellitus treatment currently relies on externally administered insulin, which lacks the precise glucose-responsive regulation of pancreatic β-cells. This study develops a synthetic glucose-responsive gene expression system using repeated glucose-responsive elements (R3G) to regulate insulin production in non-pancreatic cells. The R3G element, derived from carbohydrate response elements (ChoREs) of the liver pyruvate kinase promoter, was incorporated upstream of minimal promoters to create glucose-inducible constructs with low basal activity. Plasmid (pDNA) constructs were generated using the pGM206 backbone containing either reporter genes or a furin-cleavable human insulin cDNA (hsoINSfur). pDNA was delivered into HepG2 cells using the non-viral Glycosaminoglycan-binding Enhanced Transduction (GET) nanoparticle system. Glucose responsiveness was evaluated using Gaussia luciferase (GLuc) assays and a dual secreted reporter system incorporating secreted embryonic alkaline phosphatase (SEAP) as an internal normalisation control. Among the promoters tested, R3G-miniCMV and R3G-SCP1 demonstrated strong glucose-dependent activation while maintaining low basal expression. R3G-miniCMV produced the greatest dynamic range, showing up to ∼24-fold induction under hyperglycaemic conditions (25 mM glucose) relative to hypoglycaemic/glucose-free conditions. Dual-reporter assays confirmed that increased GLuc activity was due to glucose-responsive transcription rather than variations in transfection efficiency or cell viability/metabolism. Replacement of reporter genes with hsoINSfur demonstrated functional insulin secretion, with R3G-containing constructs producing significantly higher C-peptide levels under elevated glucose conditions compared with non-R3G controls. Overall, this study demonstrates that synthetic R3G promoters can confer robust glucose-responsive insulin expression in non-pancreatic cells using a safe non-viral delivery platform, providing a proof-of-concept system for future glucose-regulated insulin gene therapy applications.